Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937678 | 0.82 | MEN1 (0.31) | — | |
| SCHEMBL3938588 | 0.82 | ALDH1A1 (0.49) | — | |
| SCHEMBL4877435 | 0.78 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL12869507 | 0.78 | GPR142 (0.34) | MAPK1 | |
| SCHEMBL12310276 | 0.73 | ALDH1A1 (0.33) | MAPK1 | |
| SCHEMBL12258785 | 0.72 | GPR142 (0.37) | MAPK1 | |
| SCHEMBL21610732 | 0.71 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL12869685 | 0.69 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL15998439 | 0.69 | SMN1; SMN2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL1173700 | 0.68 | MAPK1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | MAPK1 2985/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | MAPK1 4791/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAPK1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.